Massive Bio Partners with Foundation Medicine to Improve Cancer Clinical Trials at ESMO24

Sep 13, 2024, 12:09 PM

Biotech company Massive Bio has announced a partnership with Foundation Medicine to enhance clinical trial recruitment and enrollment, focusing on precision cancer care. The collaboration aims to address the low enrollment rates in cancer clinical trials by leveraging AI and genomic profiling. This partnership, highlighted at the ESMO24 conference, is seen as a pivotal step in developing solutions to the cancer clinical trial enrollment paradox, potentially allowing more patients to access advanced treatments.